Gundram Jung M.D., M.Sc.

Gundram Jung studied physics, biophysics and medicine at the Universities of Karlsruhe, München, Münster and Tübingen.

Already during his time as postdoc at the Scripps Clinic and Research foundation, La Jolla (1984-1987) he came into contact with bispecific antibodies (bsAbs) and pioneered the field of T cell costimulating bsAb.

He then received training in Internal Medicine, Hematology and Oncology at the University Hospital Großhadern, Munich (1987-1999), where he headed the first clinical trial with bispecific CD28 antibodies in man.

In 2002 he was appointed as a Professor for Experimental Immunotherapy at the Department of Immunology, University of Tübingen. Here, he optimized bispecific costimulators (BiCos) and invented additional antibody formats for cancer therapy.

In 2008 he received a GoBio award by the Federal Ministry for Education and Research for the “Development, production and initial clinical evaluation of antitumor antibodies optimized by gene  technology”: resulting in the foundation of the Synimmune GmbH in 2012.

Since2015 he served as lead investigator within the German Consortium for Translational Cancer Research (DKTK). Together with Helmut Salih he has initiated several clinical trials with the reagents developed within this program.

He is author and main inventor on >100 scientific publications and numerous patents (>10) in the field of antibody therapy.

In 2023 he founded TWYCE GmbH together with Martin Pflügler and Helmut Salih.